The countdown to the new year is nearly upon us, but no need to count down to the last installment of Editors’ Picks in 2025 … because here it is! With articles on everything...
Immune checkpoint inhibitor improves survival in people with limited-stage small cell lung cancer.
At the SABCS 2025 View From the Trenches session, experts discussed how new clinical trial results might transform breast cancer care.
A year-end review of some of the new cancer treatments, exciting breakthroughs, and insights into cancer's development that emerged in 2025.
Clinical trial presented at SABCS finds some patients may safely skip sentinel lymph node biopsy.
In clinical trials presented at SABCS, a mobile health tool and acupuncture helped to improve breast cancer survivors' quality of life.
The addition of targeted therapy helps control metastatic breast cancer, and a pair of immunotherapy drugs prolongs survival in multiple myeloma.
Amid the debate over menopausal hormone therapy and cancer risk, researchers at SABCS provided some clarity for women with BRCA1/2 mutations.
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
New insights into the neurologic and physiologic impact of chronic stress on ovarian cancer were presented at two recent AACR conferences.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More